Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathon B Cohen

Showing results (31-40 of 129) with videos related to

Pageof 13
Sort By:
Blood Advances|October 26, 2021
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphomaCraig A Portell, Nolan A Wages, Brad S Kahl, et al.
Transplantation and Cellular Therapy|October 28, 2023
Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20<sup>+</sup> B Cell LymphomaJavier Munoz, Ian W Flinn, Jonathon B Cohen, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2015
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaChristopher R Flowers, Jennifer R Brown, Hilary Rosenthal, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 24, 2015
Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphomaChristine C Davis, Jonathon B Cohen, Katherine S Shah, et al.
Cancer|December 11, 2019
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 studyJonathon B Cohen, Lai Wei, Kami J Maddocks, et al.
Blood Cancer Journal|May 12, 2025
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, et al.
Blood Advances|July 6, 2022
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysisDanny Luan, Tolulope Fatola, Ahmed Toure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2022
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World CohortsPeter Martin, Jonathon B Cohen, Michael Wang, et al.
Cancer|May 26, 2018
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibMax J Gordon, Michael Churnetski, Hamood Alqahtani, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin LymphomaJonathon B Cohen, Silvana Bucur, Elliott F Winton, et al.
Pageof 13

Showing results (31-40 of 129) with videos related to

Sort By:
Pageof 13
Blood Advances|October 26, 2021
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphomaCraig A Portell, Nolan A Wages, Brad S Kahl, et al.
Transplantation and Cellular Therapy|October 28, 2023
Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20<sup>+</sup> B Cell LymphomaJavier Munoz, Ian W Flinn, Jonathon B Cohen, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 20, 2015
A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic LeukemiaChristopher R Flowers, Jennifer R Brown, Hilary Rosenthal, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 24, 2015
Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphomaChristine C Davis, Jonathon B Cohen, Katherine S Shah, et al.
Cancer|December 11, 2019
Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 studyJonathon B Cohen, Lai Wei, Kami J Maddocks, et al.
Blood Cancer Journal|May 12, 2025
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, et al.
Blood Advances|July 6, 2022
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysisDanny Luan, Tolulope Fatola, Ahmed Toure, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2022
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World CohortsPeter Martin, Jonathon B Cohen, Michael Wang, et al.
Cancer|May 26, 2018
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibMax J Gordon, Michael Churnetski, Hamood Alqahtani, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin LymphomaJonathon B Cohen, Silvana Bucur, Elliott F Winton, et al.
Pageof 13